S2-Hydroxyglutarate Utilization as a Target for Therapy in the IDH Mutant Pediatric High-Grade Glioma

Jacob Paris Introduction: Pediatric high-grade gliomas (pHGG) are the most common central nervous system tumors diagnosed in children and have a very poor prognosis. This diagnosis has a typical post-diagnosis survival of 5.6 months after intervention1-3. New research has shown that the classification of these tumors by gene mutations shows…
Cancer Engineering Medicine

The Role of CXCR2 and its Associated Ligands in the Progression and Management of Colorectal Cancer

Michael Geng Introduction: Colorectal cancer (CRC) is the third most common cancer and second most lethal cancer globally.1,3,4 Twenty percent of patients present with metastatic CRC when diagnosed, and an additional 25% of patients who present with local disease will develop metastatic CRC during their treatment course.1 In recent decades, increasing evidence…
Cancer Engineering Medicine

Downregulation of IL-1B Pathway in Tumor Microenvironment Demonstrates Therapeutic Potential in Slowing Proliferation and Development of Breast Cancer Bone Metastases

Pujita Munnangi Introduction. Breast cancer (BC) is the most prevalent form of cancer impacting women across the globe; 75% of patients with stage IV BC develop bone metastases.1 Skeletal metastases lead to increased risk of fractures, weakened bones, severe pain and disability, and decreased mobility due to the development of…
Cancer Engineering Medicine Featured Abstracts

Novel Immunotherapies such as CD22-targeted CAR T Cells and Anti-CD19 scFv hCAR T Cells May Offer Solutions for Relapsed/Refractory B cell Acute Lymphoblastic Leukemia

Jeffery White Introduction: B cell acute lymphoblastic leukemia (B-ALL) is the most prevalent type of cancer in children.1,2 B-ALL arises when the highly regulated process of differentiation of hematopoietic stem cells to mature B cells goes awry.1,3 Managed by multiple tightly regulated processes, it is difficult for a faulty B cell to escape termination.…
Cancer